Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Peifa Zhang"'
Autor:
Xiaojuan Pang, Guochuang Chen, Ping Huang, Peifa Zhang, Jie Liu, Xiaohu Hou, Cheng-Yi He, Ping Chen, Yi-Wu Xie, Jing Zhao, Zhi-Ying Chen
Publikováno v:
Molecular Therapy: Oncolytics, Vol 24, Iss , Pp 788-798 (2022)
Bispecific antibodies (BsAbs) are a class of promising anticancer immunotherapies. Among them, the US Food and Drug Administration (FDA)-approved blinatumomab (BLI) is very effective in eliminating the minimum residual disease (MRD) of acute lymphobl
Externí odkaz:
https://doaj.org/article/ca0bf43bc0464958a831d0295af6708b
Autor:
Jing Zhao, Ping Chen, Chen Guochuang, Pang Xiaojuan, Zhiyong Wang, Zhi-Ying Chen, Cheng-Yi He, Xie Yiwu, Peifa Zhang, Xiaohu Hou
Publikováno v:
Biomaterials. 250:120072
Ovarian cancer has become one of the most common gynecological cancers with a high mortality. However, conventional surgery together with combination chemotherapy is difficult to achieve ideal therapeutic effect. Although genetic immunotherapy is app
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbeadaa6fe19efdee46801b7bcaaf3a6
https://doi.org/10.1016/j.biomaterials.2020.120072
https://doi.org/10.1016/j.biomaterials.2020.120072
Autor:
Liu Yunhong, Jing Zhao, Zhiyong Wang, Xiaojuan Pang, Xiaohu Hou, Pingzhang Chen, Chen Zhiying, He Chengyi, Ping Chen, Peifa Zhang
Publikováno v:
Biomaterials science. 6(3)
Bispecific T-cell engagers (BiTEs) are single chain variable fragments with specific structures, which could connect the surface antigen on cancer cells and CD3 ligands on T cells, and then engage the T cells for cancer immunotherapy. In this report,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eba7bad0af4f1a4e59e43a0293dd9ecb
https://pubmed.ncbi.nlm.nih.gov/29411792
https://pubmed.ncbi.nlm.nih.gov/29411792